Figure 3 | Scientific Reports

Figure 3

From: Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

Figure 3

Graphical representation of the experimental designed followed in this study. First, we characterized the molecular profile of HFpEF and Empagliflozin (Panels 1 and 2). Next, we used experimental, RNAseq data to frame the behaviour of the future mathematical models (Panel 3). Then, we built a series of algorithms based on artificial intelligence techniques to elucidate the most prominent mechanism of action at play that could describe the clinical improvements observed in patients (Panel 4). Finally, we validated these findings in a small cohort of patients before and after being treated with empagliflozin, to delineate a specific signalling cascade (Panels 5 and 6). ECM: Extracellular matrix; HFpEF: heart failure with preserved ejection fraction; DM: diabetes mellitus.

Back to article page